Improving Patients’ Quality of Life After Surgical Treatment of Primary Malignant Bone Tumors Using a Training 3D Model
DOI:
https://doi.org/10.15407/exp-oncology.2024.04.341Keywords:
bone tumors, osteosarcoma, chondrosarcoma, treatment, 3D-models, personalized treatment, quality of lifeAbstract
Background. Bone neoplasms significantly reduce the patient’s quality of life (QoL) not only during the manifestation of the primary disease but also at various treatment stages. Aim. To study the QoL indicators in patients with primary malignant bone tumors before and after surgical treatment using a training 3D model. Materials and Methods. 44 patients with primary malignant tumors of the lower extremities (osteosarcoma and chondrosarcoma) were treated by surgery. 3D modeling was used to plan the surgical intervention. 3D printing of the models of the pathological foci was performed by the method of layer-by-layer deposition (Fused Deposition Modeling, FDM) using a Creatbot D600 3D printer. The QoL index of patients before and 3 weeks after surgical treatment was measured by the arithmetic sum of the scores of the QLQ-C30 simplified version questionnaire. Results. The surgical removal of a tumor using a training 3D model had a positive effect on the QoL of patients. Before treatment, the QoL index was on average 7.4 ± 1.2 points, and after treatment 9.4 ± 1.3 points, that is, by 27% higher. Conclusions. The use of training 3D models not only implements a strategy of personalized treatment and improves the QoL of patients but also contributes to optimization of the postoperative rehabilitation.
References
Panagi M, Pilavaki P, Constantinidou A, Stylianopoulos T. Immunotherapy in soft tissue and bone sarcoma: Unravel- ing the barriers to effectiveness. Theranostics. 2022;12:6106-6129. https://doi.org/10.7150/thno.72800
Mettmann VL, Blattmann C, Friedel G, et al. Primary multi-systemic metastases in osteosarcoma: presentation, treat- ment, and survival of 83 patients of the Cooperative Osteosarcoma Study Group. Cancers (Basel). 2024;16(2):275. https://doi.org/ 10.3390/cancers16020275
Ren J, Zhao C, Sun R, et al. Augmented drug resistance of osteosarcoma cells within decalcified bone matrix scaffold: The role of glutamine metabolism. Int J Cancer. 2024;154(9):1626-1638. https://doi.org/10.1002/ijc.34841
Zhu Y, Wu X, Zhang W, Zhang H. Limb-salvage surgery versus extremity amputation for early-stage bone cancer in theextremities: apopulation-basedstudy. Front Surg. 2023;10:1147372. https://doi.org/10.3389/fsurg.2023.1147372
Panez-Toro I, Muñoz-García J, Vargas-Franco JW, et al. Advances in Osteosarcoma. Curr Osteoporos Rep. 2023;21(4):330-343. https://doi.org/10.1007/s11914-023-00803-9.
Leng Y, Li J, Long Z, et al. Osteoblast-derived exosomes promote osteogenic differentiation of osteosarcoma cells via URG4/Wnt signaling pathway. Bone. 2024;178:116933. https://doi.org/10.1016/j.bone.2023.116933
Gerrand C, Athanasou N, Brennan B, et al. UK guidelines for the management of bone sarcomas. Clin Sarcoma Res. 2016;6:7. https://doi.org/10.1186/s13569-016-0047-1
Wang L, Li W, Pan Y. The Eph/Ephrin system in primary bone tumor and bone cancer pain. Aging (Albany NY). 2023;15(14):7324-7332. https://doi.org/10.18632/aging.204852
Zhang Q, Yang Y, You X, et al. Comprehensive genomic analysis of primary bone sarcomas reveals different genetic pat- terns compared with soft tissue sarcomas. Front Oncol. 2023;13:1173275. https://doi.org/10.3389/fonc.2023.1173275
Roberts RD, Lizardo MM, Reed DR, et al. Provocative questions in osteosarcoma basic and translational biology: A report from the Children’s Oncology Group. Cancer. 2019;125:3514-3525. https://doi.org/10.1002/cncr.32351
Salom M, Chiari C, Alessandri JMG, et al. Diagnosis and staging of malignant bone tumours in children: what is due and what is new? J Child Orthop. 2021;15(4):312-321. https://doi.org/10.1302/1863-2548.15.210107
Bartelstein MK, Boland PJ. Fifty years of bone tumors. J Surg Oncol. 2022;126(5):906-912. https://doi.org/10.1002/ jso.27027.
de Ligt KM, Aaronson NK, Liegl G, Nolte S; EORTC Quality of Life Group. Updated normative data for the EORTC QLQ-C30 in the general Dutch population by age and sex: a cross-sectional panel research study. Qual Life Res. 2023;32(9):2477-2487. https://doi.org/ 10.1007/s11136-023-03404-2.
Gazendam A, Popovic S, Parasu N, Ghert M. Chondrosarcoma: A clinical review. J Clin Med. 2023;12(7):2506. https://doi.org/10.3390/jcm12072506
Paulino Pereira NR, Janssen SJ, et al. Physical function and quality of life after resection of mobile spine chondrosar- coma. Global Spine J. 2019;9(7):743-753. https://doi.org/ 10.1177/2192568219830330
Fernando-Canavan L, Abraham P, Devlin N, Tran-Duy A. Health-related quality of life in patients with extremi- ty bone sarcoma after surgical treatment: a systematic review. Qual Life Res. 2024;33(5):1157-1174. https://doi. org/10.1007/s11136-023-03554-3
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Experimental Oncology

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.